# A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

Study · id `cardio:ct-nct05425056` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05425056](<https://clinicaltrials.gov/study/NCT05425056>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05425056

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

## Technical summary

Registry record NCT05425056. Randomized; triple masking; primary purpose prevention. Start 2022-08-26 (actual); primary completion 2025-03-18 (actual). Results posted on 2026-10-06.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 136 participants (enrolled count; ClinicalTrials.gov record NCT05425056, source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)
- Started: 2022-08-26 (actual) (ClinicalTrials.gov record NCT05425056, source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)
- Primary completion: 2025-03-18 (actual) (ClinicalTrials.gov record NCT05425056, source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)
- Completion: 2025-08-29 (actual) (ClinicalTrials.gov record NCT05425056, source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)
- Results first posted: 2026-10-06 (ClinicalTrials.gov record NCT05425056, source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)
- Countries: United States; United Kingdom (ClinicalTrials.gov record NCT05425056, source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05425056-2026-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
- Acronym: ACCESS2
- Condition: Complication of Renal Dialysis
- Condition: End Stage Renal Disease
- Condition: End Stage Kidney Disease
- Condition: ESRD
- Condition: Chronic Kidney Failure
- Condition: Complication of Hemodialysis
- Condition: Vascular Access Complication
- Condition: Arteriovenous Fistula
- Intervention (Drug): Sirolimus
- Lead sponsor: Vascular Therapies, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 0fdc90a4b92bed070b457b4e8c85148c9e5d10d81d128cf0d75cc6172f65cdba
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
